PET Pharm Biotech Co., Ltd.
TTPEX:776250.70
TWD
-0.70
(-1.36%)
ISIN
TW0007762007
Return %
Stock
S&P 500
1Y
-35.19
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Semi-annual Revenue
TWD
•
in mil. unless spec.Semi-annual Earnings Per Share
TWD
•
in mil. unless spec.Semi-annual Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Liang Kuang Lin
- Full Time Employees
- 60
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- New Taipei City Taiwan
- IPO Date
- Jul 26, 2024
- Website
- petpharmbio.com
- Similar Companies
- Business
- PET Pharm Biotech Co., Ltd. is a Taiwan-based veterinary pharmaceutical and animal biotechnology company specializing in the research, development, manufacturing, and commercialization of animal therapeutics, nutritional feed additives, and companion animal healthcare products. The company operates through two core business segments: Livestock and Aquaculture Health, and Companion Animal Care. Its comprehensive product and service portfolio encompasses veterinary pharmaceuticals, including prescription antimicrobials, antiparasitics, anti-inflammatory agents, analgesics, hormones, and metabolic regulators for swine, poultry, cattle, and aquatic species; animal nutrition and feed additives, comprising specialized probiotic blends, organic acid complexes, digestive enzymes, electrolyte formulations, and concentrated vitamin-mineral premixes designed to enhance feed conversion and livestock immunity; companion animal healthcare products, featuring veterinary-grade joint health supplements, dermatological therapies, gastrointestinal conditioners, ocular and otic care solutions, and oral hygiene products; biosecurity and agricultural sanitation solutions, including veterinary-grade environmental disinfectants and disease prevention agents; and contract development and manufacturing organization (CDMO) services for veterinary medicines and specialized nutritional formulations. Founded in 2020 as part of the YungShin Global Holding group and headquartered in Taichung, Taiwan, the company distributes its products to veterinary hospitals, livestock and poultry farms, feed mills, agricultural distributors, and pet specialty retailers across Taiwan, as well as export markets in East Asia and Southeast Asia. In recent major developments, the company listed its shares on the Taiwan Emerging Stock Board under ticker 7762 in March 2024 to accelerate business expansion and capital growth. Furthermore, PET Pharm Biotech Co., Ltd. has actively expanded its companion animal therapeutic pipeline, modernized its PIC/S GMP-certified manufacturing infrastructure to increase production capacity, and established new strategic distribution alliances across key Southeast Asian markets, including Vietnam, the Philippines, and Thailand, to broaden its international market presence.